Abstract: Objective: To assess the efficacy of modified docetaxel, cisplatin and 5-fluorouracil (mDCF) chemotherapy in patients with advanced gastric adenocarcinoma. Methods: From January 2006, 45 patients with advanced gastric cancer were enrolled and treated with mDCF protocol. The mDCF protocol included docetaxel 60mg/m2 on d1, cisplatin 12mg/m2 on d1～5 and 5-fluorouracil 2 500 mg/m2 continuous infusion (civ) for 120h, every 3 weeks. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were overall survival(OS), response rate(RR) and side effects. Results: In 40 patients who received mDCF as first-line palliative chemotherapy, no patient achieved complete response, 7(17.5%) had partial response, 9(47.5%) had stable disease, and 14(35%) showed progressive disease. Overall response rate was 17.5%（95%CI 7.5%～30.0%）and disease control rate was 65.0%（95%CI 50.0%～77.5%）. Median PFS was 5.2 months（95%CI 3.6～6.8 months）and median OS was 11.0 months（95%CI 6.9～15.1months）. In 5 patients who received mDCF as second-line palliative chemotherapy, 3 achieved stable disease and 2 had progressive disease. Median PFS was 5.3 months(95%CI 0～11.3 months) and median OS was 8.5 months（95%CI 0～17.1 months）. Major side effects were hematologic effects. The rates of grade 3/4 neutropenia, neutropenia with fever, nausea, vomiting and diarrhea were 26.7%，11.1%, 8.9%, 8.9% and 11.1% respectively. Conclusion: The mDCF regimen is effective with a favorable toxicity profile.

Key words: Advanced gastric cancer, chemotherapy, docetaxel, cisplatin, 5-fluorouracil